Sign in
CML clonal evolution with resistance to single agent imatinib therapy
Journal article

CML clonal evolution with resistance to single agent imatinib therapy

R Swords, J Quinn, M Fay, R O'Donnell, J Goldman and P T Murphy
Clinical and laboratory haematology, Vol.27(5), pp.347-349
2005-10
PMID: 16178920

Abstract

Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzamides Cell Transformation, Neoplastic - chemically induced Cell Transformation, Neoplastic - genetics Clone Cells - pathology Cytarabine - therapeutic use Drug Resistance, Neoplasm Humans Hydroxyurea - therapeutic use Imatinib Mesylate Interferon-alpha - therapeutic use Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Male Middle Aged Philadelphia Chromosome Piperazines - adverse effects Piperazines - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Remission Induction - methods Treatment Failure Trisomy

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics
1 Clinical & Life Sciences
1.103 Blood Disorders
1.103.1126 Chronic Myeloid Leukemia
Web Of Science research areas
Hematology
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details